NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL
about
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsDeciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolutionClinical implications of the molecular genetics of chronic lymphocytic leukemiaThe biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaThe pathogenesis of chronic lymphocytic leukemiaClinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondRecurrent mutations refine prognosis in chronic lymphocytic leukemia.Detection of clonal blood cells with specific chromosomal abnormalities in the general populationIntegrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaCXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data.Network-Based Integration of Disparate Omic Data To Identify "Silent Players" in CancerSecond cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaNOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas.HES1 is an independent prognostic factor for acute myeloid leukemia.The double-edged sword of Notch signaling in cancer.The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.Molecular pathogenesis of chronic lymphocytic leukemia.Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US iClinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.The spectrum of genetic defects in chronic lymphocytic leukemia.Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemiaA Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemiaSpliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies.Molecular genetics of high-risk chronic lymphocytic leukemia.New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression.
P2860
Q26764833-1F86CE84-FF57-4D19-BEEC-EFFCA66A33DAQ26823586-839684C9-9FB1-44B8-8F3C-F5E43A8A9E4EQ26830955-EE15A003-42D5-43A6-9031-8162511AFEA3Q27024411-24E4CB27-8B7B-4449-8A6F-FFECAE89BBC6Q27025715-228F92E9-F988-4BBB-863A-CE11F7AEB939Q27027493-9F43555B-2537-4C7D-8DC0-73323937810CQ27853022-9A65DA00-8B95-4D28-81D6-74772FD680EEQ28386348-E116B54B-5238-4547-BC38-5D1D2F09143DQ28394721-FDE9A6CC-7BEC-43B6-BC7F-1D87C529EE27Q30657004-1D0C53D6-0B25-43F5-B71F-E93872EC36B6Q30685440-E60C5EEB-D34F-43F4-AB4C-051A9A6061DFQ31032861-6979F91E-1F26-444C-A958-E237A5C26E4EQ33421376-49487C5F-014E-4430-B73B-A41AD9BF31E1Q33648906-050B833F-1C9D-4BEB-B12E-BE767CF8FD9BQ34293927-5309FBA1-3FE7-4518-8927-695BEB6BFCCAQ34453174-2D02CECF-76A0-4CE2-89C8-E8FFD02EA5C6Q34756505-DF91FC0B-42C2-481E-9827-A03BD5E5E38EQ34794876-76EEA9B6-BE01-432A-B865-0FABDEF8DF1AQ35146301-D1A6B0A1-7B11-4F10-B6FA-D53389ED415FQ35149661-52F9385C-53F9-48ED-B70C-8FC9C78D063EQ35172559-E88DACAF-B4A5-4720-897D-7ED02040CD7BQ35331179-C6FA9B33-BA59-4A64-BC5F-67BB6E673D1AQ35541938-BF1E9B99-51AE-43C3-8152-DBD0F6D6C1C1Q35989577-BC8A2500-C3A6-4145-8CF9-E1D9BB4A91AEQ36150234-33FB50D5-5BD8-4320-8762-46CFC7F02C8DQ36290321-199A57EA-6BE2-4C53-BF53-27B37AC1CED4Q36397924-795C222B-8805-426D-8462-C7939B014355Q36420752-96F55DAF-A43D-4599-B24A-D63B402891FAQ36426587-B5F196D2-86C1-4B43-A6FF-0F45F08A99D1Q36981193-6E15B23A-606F-4462-B0E5-4C5B50EA4BA6Q37542431-4A555783-C825-4AB2-A483-0259BC73E5ECQ37618663-09D9B6B8-9EA2-45C9-87EF-B78E057F831AQ37699259-755A80E7-04E3-4609-9C2D-06C078978C99Q38000919-F195A3F1-410A-4454-A5DA-2F33A24DCF7DQ38061177-AF85810A-899F-433E-A447-60F8D8C0093AQ38065304-F95704AC-51EC-4072-BA4A-B006A280FE50Q38076190-3D34400C-4D8F-4D39-BF73-75757D060157Q38088354-4EEA7ADF-4963-4283-82D2-887616AC119BQ38185363-51D12763-CED4-4391-9BFF-41F20980CF06Q38262761-4E7A0672-841E-4F54-AD22-5029664CFE8C
P2860
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@ast
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@en
type
label
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@ast
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@en
prefLabel
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@ast
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@en
P2093
P2860
P1433
P1476
NOTCH1 mutations in +12 chroni ...... ermediate prognosis of +12 CLL
@en
P2093
Anna Guarini
Davide Rossi
Ilaria Del Giudice
Luca Laurenti
Marco Fangazio
Marilisa Marinelli
Roberto Marasca
Sabina Chiaretti
Sara Gabrielli
Silvia Rasi
P2860
P304
P356
10.3324/HAEMATOL.2011.060129
P577
2011-12-29T00:00:00Z